Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Abstract Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are p...

Full description

Bibliographic Details
Main Authors: Yuko Shirouchi, Noriko Nishimura, Yuko Mishima, Yuko Ishihara, Hiroaki Asai, Mikako Tamba, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Kengo Takeuchi, Takashi Terauchi, Dai Maruyama
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-40026-7

Internet

https://doi.org/10.1038/s41598-023-40026-7

Similar Items